Barinthus Biotherapeutics plc
BRNS
$0.72
-$0.02-2.64%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 31.05% | -7.51% | 4.34% | -153.14% | 52.08% |
| Total Depreciation and Amortization | -91.59% | -2.67% | 96.50% | -6.96% | 1.20% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | 37.02% | 12.74% | -83.29% | 356.63% | 86.46% |
| Change in Net Operating Assets | 33.48% | -1,504.38% | -100.90% | 199.08% | -1,150.27% |
| Cash from Operations | 40.77% | -21.52% | -213.88% | 171.91% | -51.57% |
| Capital Expenditure | 100.00% | -540.00% | 98.20% | -143.86% | 40.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 1,509.38% | -540.00% | 98.20% | -143.86% | 40.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -99.76% | 80.00% | 29.89% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -100.00% | -99.76% | 80.00% | 29.89% |
| Foreign Exchange rate Adjustments | -134.32% | 73.35% | 141.98% | -218.98% | 1,829.69% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.35% | -8.24% | -287.69% | 153.96% | 4.30% |